

Emerging Immune Checkpoints Beyond PD-1/PD-L1 in Solid Tumor Immunotherapy

Alina Svoboda, Amandine Marchand, Milan Oliveira

Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia

Abstract.

The landscape of oncological therapeutics has been fundamentally transformed by the advent of immune checkpoint inhibitors, particularly those targeting the programmed cell death protein 1 and its primary ligand. Despite the unprecedented and durable clinical responses observed in a subset of patients across various solid malignancies, primary and acquired resistance remain formidable challenges, thereby limiting the universal applicability of these therapeutic modalities. This comprehensive academic paper investigates the biological mechanisms, preclinical validation, and clinical trajectory of emerging immune checkpoints that function beyond traditional pathways. We systematically evaluate the structural characteristics, ligand interactions, and signaling cascades of novel co-inhibitory receptors, including Lymphocyte activation gene 3, T-cell immunoglobulin and mucin-domain containing-3, T cell immunoreceptor with Ig and ITIM domains, and V-domain Ig suppressor of T cell activation. Through a detailed analytical framework encompassing pan-cancer transcriptomic profiling and clinical trial meta-analyses, this study elucidates the complex temporal and spatial expression patterns of these molecules within the tumor microenvironment. Our findings indicate that the concurrent expression of these alternative checkpoints often serves as a compensatory resistance mechanism following conventional immunotherapy. Furthermore, we provide an extensive discussion on the synergistic potential of combinatorial blockade strategies designed to overcome immune exhaustion and restore robust anti-tumor effector functions. The integration of high-dimensional biomarker discovery and precision immunology is emphasized as a critical requisite for optimizing patient stratification and mitigating immune-related adverse events in the next generation of solid tumor immunotherapy.

Keywords:

Immunotherapy,
Tumor
Microenvironment, Co-
inhibitory Receptors,
Immune Exhaustion.

1. INTRODUCTION

The historical progression of cancer treatment has been characterized by iterative paradigms, transitioning from broad cytotoxic interventions to highly targeted precision therapies. In recent decades, the conceptualization and subsequent clinical translation of cancer immunotherapy have arguably represented the most significant breakthrough in clinical oncology. The immune system, through its intricate network of surveillance and effector mechanisms, possesses the intrinsic capacity to recognize and eliminate neoplastic cells. However, tumors evolutionarily adapt to evade this immune surveillance through a process termed immunoediting, which ultimately results in immune escape and unchecked malignant proliferation. Central to this mechanism of immune

evasion is the hijacking of physiological immune checkpoints, which are innate regulatory pathways designed to maintain self-tolerance, prevent autoimmunity, and protect tissues from collateral damage during physiological inflammatory responses [1]. The therapeutic blockade of these inhibitory pathways, particularly cytotoxic T-lymphocyte-associated protein 4 and programmed cell death protein 1, has validated the hypothesis that the endogenous immune system can be therapeutically uncoupled from tumor-induced suppression. Monoclonal antibodies targeting the programmed cell death protein 1 axis have revolutionized the treatment algorithms for a multitude of solid tumors, including non-small cell lung cancer, melanoma, renal cell carcinoma, and urothelial carcinoma [2]. By preventing the interaction between the receptor on exhausted T cells and its specific ligands expressed on both tumor cells and antigen-presenting cells, these agents effectively release the brakes on the immune system, allowing for the restoration of robust cytotoxic activity. Despite these monumental clinical successes, a sobering reality persists within the oncological community. The objective response rates for single-agent programmed cell death protein 1 blockade typically range between twenty and thirty percent in unselected solid tumor populations. A substantial proportion of patients exhibit primary resistance, characterized by an inherent lack of initial response, while others develop acquired resistance after an initial period of clinical benefit [3]. The biological underpinnings of this resistance are intensely complex and multifaceted, involving an interplay between tumor-intrinsic factors, such as the absence of neoantigens or defective antigen presentation machinery, and tumor-extrinsic factors driven by the cellular composition of the tumor microenvironment. It has become increasingly evident that the exhaustion of tumor-infiltrating lymphocytes is not mediated by a single inhibitory receptor, but rather by an entire network of co-inhibitory molecules that are dynamically and frequently co-expressed. The prolonged exposure to tumor antigens in the context of a highly immunosuppressive milieu induces a progressive state of T cell dysfunction, marked by hierarchical loss of effector capabilities, altered transcriptional and epigenetic landscapes, and the sustained upregulation of multiple alternative immune checkpoints [4]. Consequently, when one inhibitory pathway is therapeutically antagonized, the redundant nature of the immune system allows for compensatory upregulation of parallel suppressive networks, thereby effectively neutralizing the anti-tumor response and facilitating continued malignant progression. This biological reality has catalyzed a massive paradigm shift in immunological research, redirecting focus toward the identification, characterization, and therapeutic targeting of emerging immune checkpoints beyond the conventional pathways. Understanding the unique spatial distribution, temporal expression kinetics, and distinct intracellular signaling cascades of these novel co-inhibitory receptors is paramount for the rational design of next-generation immunotherapeutic combinations. The primary objective of this paper is to provide an exhaustive examination of these alternative immune checkpoints in the context of solid tumor immunology. We will explore the fundamental biology of these receptors, their specific roles in modulating the complex cellular dynamics within the tumor microenvironment, and the current landscape of clinical and preclinical efforts aimed at translating these biological insights into effective patient treatments. By systematically deconstructing the mechanisms of novel inhibitory pathways, this research aims to highlight the critical necessity of moving beyond monotherapy approaches. The future of solid tumor immunotherapy undoubtedly lies in combinatorial strategies that can simultaneously target multiple non-redundant nodes of immune suppression. However, the realization of this potential requires a profound understanding of immune-related toxicities, sophisticated biomarker discovery to identify optimal patient subsets, and rigorous analytical frameworks to evaluate complex biological data. Through a detailed exploration of the literature and advanced analytical

methodologies, this paper endeavors to contribute to the foundational knowledge required to overcome current therapeutic plateaus and advance the field of precision immuno-oncology.

2. Literature Review and Biological Background

The conceptual expansion of the immune checkpoint landscape requires a granular understanding of the specific molecular interactions that dictate immune cell fate within the tumor microenvironment. The complex regulatory networks governing T cell activation, proliferation, and effector function are modulated by an array of co-stimulatory and co-inhibitory receptors. Over the past decade, extensive preclinical investigation has identified several distinct molecules that play pivotal roles in maintaining tumor-induced immunosuppression, independent of traditional pathways.

2.1 Lymphocyte-Activation Gene 3

Lymphocyte-activation gene 3, also designated as CD223, was among the first alternative inhibitory receptors to be comprehensively characterized. Structurally, it is a transmembrane protein with significant homology to the CD4 co-receptor, containing four extracellular immunoglobulin-like domains. It is primarily expressed on the surface of activated CD4-positive and CD8-positive T cells, regulatory T cells, natural killer cells, and certain populations of dendritic cells [5]. The primary canonical ligand for this receptor is the major histocompatibility complex class II. Due to its structural similarity to CD4, it exhibits a significantly higher binding affinity for major histocompatibility complex class II molecules, thereby actively competing with CD4 and sterically hindering optimal T cell receptor complex formation and subsequent signal transduction. Recent structural and biochemical studies have revealed that the inhibitory capacity of this receptor extends beyond simple competition. Upon binding to its ligands, specific intracellular motifs within its cytoplasmic tail, including the highly conserved KIEELE motif, transmit potent negative regulatory signals that directly attenuate T cell proliferation and cytokine production [6]. Furthermore, the complexity of its regulatory network has been expanded by the identification of alternative, independent ligands. Fibrinogen-like protein 1, secreted by the liver and frequently aberrantly overexpressed by human cancer cells, has been identified as a major functional ligand that suppresses T cell activation independently of major histocompatibility complex class II interactions. The dual ligand binding capacity underscores the multifaceted role of this checkpoint in mediating immune evasion and provides a strong biological rationale for its therapeutic targeting.

2.2 T-Cell Immunoglobulin and Mucin-Domain Containing-3

Another critical mediator of immune exhaustion is T-cell immunoglobulin and mucin-domain containing-3. Originally identified as a specific marker for fully differentiated T helper 1 and cytotoxic T cell subsets, this molecule has subsequently been recognized as a potent inhibitory receptor broadly expressed across various innate and adaptive immune cell lineages, including regulatory T cells, macrophages, and dendritic cells [7]. Unlike receptors that compete for co-stimulatory binding sites, this molecule modulates immune responses through a diverse array of distinct ligands, each interacting with specific domains of the receptor to trigger unique downstream effects. Galectin-9 was the first recognized ligand, and its interaction with the immunoglobulin variable domain of the receptor induces calcium influx, resulting in the selective apoptosis of antigen-specific effector T cells [8]. Additionally, high mobility group box 1 protein, typically functioning as a pro-inflammatory alarmin when released from dying cells, can bind to this receptor. This interaction paradoxically dampens the immune response by preventing the transportation of nucleic acids into endosomes, thereby inhibiting the activation of innate immune sensing pathways. The promiscuity of ligand binding makes this checkpoint a highly versatile

instrument of immunosuppression, capable of dynamically responding to various cellular stresses within the localized microenvironment.

2.3 T Cell Immunoreceptor with Ig and ITIM Domains

T cell immunoreceptor with Ig and ITIM domains has emerged as a particularly compelling target due to its intricate involvement in a complex network of interacting receptors and ligands, conceptually analogous to the classical CD28 and cytotoxic T-lymphocyte-associated protein 4 paradigm. This receptor is highly upregulated on exhausted cytotoxic T cells and tumor-infiltrating regulatory T cells [9]. It functions within a competitive binding network involving the co-stimulatory receptor CD226. Both receptors compete for binding to the poliovirus receptor and Nectin-2, which are frequently overexpressed on the surface of diverse solid tumor cells.

This co-inhibitory molecule exhibits a substantially higher binding affinity for the poliovirus receptor compared to its co-stimulatory counterpart. Consequently, it outcompetes the activation signal, while its intracellular immunoreceptor tyrosine-based inhibitory motif directly recruits phosphatases that dismantle the signaling cascades initiated by the T cell receptor [10]. Beyond the direct suppression of effector cells, signaling through this specific axis on regulatory T cells significantly enhances their suppressive capacity and stability, creating a dual mechanism of immune evasion that profoundly skews the microenvironment toward profound immunotolerance.

2.4 V-Domain Ig Suppressor of T Cell Activation

V-domain Ig suppressor of T cell activation represents a unique structural and functional entity within the extended B7 family of immune regulatory molecules. Unlike the previously discussed targets, which predominantly function as receptors on the surface of lymphocytes, this molecule possesses the remarkable capability to function as both a ligand expressed on antigen-presenting cells and tumor cells, and as an inhibitory receptor on T cells [11]. It is most prominently expressed within the myeloid compartment, particularly on tumor-associated macrophages and myeloid-derived suppressor cells. A defining characteristic of this specific checkpoint is its profound dependency on the physicochemical properties of the tumor microenvironment. Research has definitively demonstrated that the structural conformation and subsequent binding affinity of this molecule are tightly regulated by extracellular pH levels. In the characteristically acidic environment of solid tumors, driven by the Warburg effect and hypoxic metabolic shifts, this protein undergoes a conformational transition that exposes critical binding residues [12]. This pH-dependent activation specifically suppresses the responses of infiltrating lymphocytes in spatially restricted areas of metabolic stress, highlighting an evolutionary adaptation of tumors to exploit local metabolic dysregulation for immune evasion.

Table 1: Target Profile and Primary Ligands for Emerging Immune Checkpoints

Checkpoint Molecule	Primary Cellular Expression	Major Known Ligands	Primary Immunological Function
Lymphocyte-activation gene 3	Activated T cells, Natural Killer cells	Major histocompatibility complex II, Fibrinogen-like protein 1	Competes with CD4, inhibits cellular proliferation
T-cell immunoglobulin mucin-3	T helper 1 cells, Macrophages	Galectin-9, High mobility group box 1	Induces effector cell apoptosis, limits innate sensing

T cell immunoreceptor with ITIM	Exhausted T cells, Regulatory T cells	Poliovirus receptor, Nectin-2	Competes with CD226, enhances regulatory cell stability
V-domain Ig suppressor	Tumor-associated macrophages, Myeloid cells	P-selectin glycoprotein ligand-1	Mediates pH-dependent suppression of activation

3. Methodology and Analytical Framework

To systematically evaluate the overarching impact and therapeutic potential of these emerging non-classical checkpoints across diverse solid malignancies, a comprehensive analytical framework was designed. This methodology integrates high-dimensional pan-cancer transcriptomic profiling, extensive cellular deconvolution techniques, and a rigorous meta-analytical synthesis of available contemporary clinical trial data. The objective of this methodological approach is to provide a robust, data-driven foundation that elucidates the spatial distribution, co-expression networks, and prognostic implications of these molecules in large patient cohorts.

3.1 Data Acquisition and Cohort Assembly

The foundational data utilized for this analytical framework were procured from extensively curated public genomic repositories. Transcriptomic data, specifically bulk RNA sequencing profiles, along with corresponding extensive clinical metadata, were systematically downloaded for thousands of patient samples representing over twenty distinct solid tumor histologies [13]. The inclusion criteria were strictly defined to ensure high data fidelity and biological relevance. Only primary tumor samples from patients with complete overall survival and progression-free survival data were retained for subsequent evaluation. Metastatic samples and tissues lacking matched normal adjacent controls were excluded to prevent confounding variables associated with systemic biological alterations or disparate treatment histories [14]. Following the initial acquisition, the raw sequencing counts underwent a rigorous preprocessing pipeline. The data were normalized to transcripts per million to account for variations in sequencing depth and gene length, thereby enabling accurate cross-sample comparisons. To further stabilize the variance across the highly heterogeneous dataset, a base-two logarithmic transformation was systematically applied [15]. Extensive quality control measures, including principal component analysis and hierarchical clustering, were employed to identify and exclude biological outliers and technical artifacts. Batch effects arising from different sequencing platforms and temporal processing variations were mathematically mitigated using empirical Bayes frameworks, ensuring that the downstream analyses reflected true biological variations rather than technical noise.

3.2 Immune Cell Deconvolution and Spatial Estimation

Bulk tumor tissue represents a highly complex amalgam of malignant cells, stromal elements, and diverse immune cell populations. To accurately ascertain the specific origins of the immune checkpoint expression signatures, advanced computational deconvolution algorithms were deployed. The relative abundances of distinct tumor-infiltrating immune cell subsets were estimated utilizing standardized deconvolution matrices [16]. This approach relies on established reference gene expression profiles of sorted leukocyte populations to infer the proportional representation of each specific cell type within the bulk tumor mass. To complement this relative quantification, single-sample gene set enrichment analysis was independently conducted to calculate absolute enrichment scores for specific immunological phenotypes, such as cytolytic activity and interferon-gamma signaling pathway activation [17]. By computing the statistical correlation coefficients between the continuous expression variables of the target immune checkpoints and the estimated infiltration levels of specific immune cell subsets, a detailed

cartography of the microenvironmental architecture was constructed. This allowed for the precise determination of whether high expression of a specific novel receptor was driven predominantly by the accumulation of regulatory T cells, exhausted cytotoxic lymphocytes, or specific immunosuppressive myeloid lineages.

3.3 Statistical Modeling and Meta-Analysis

The prognostic significance of the target checkpoints was evaluated utilizing comprehensive survival analyses. Univariate and multivariate Cox proportional hazards regression models were systematically constructed to calculate hazard ratios, incorporating critical clinical covariates such as patient age, biological sex, tumor stage, and histological grade to adjust for potential confounding effects. The proportional hazards assumptions were rigorously tested using statistical analysis of the scaled Schoenfeld residuals. Patients were subsequently stratified into specific risk categories based on optimally determined expression cut-points, and survival probabilities were visually depicted using standard product-limit estimators. Concurrently, a rigorous systematic review and meta-analysis of prospective clinical trials investigating agents targeting these specific novel pathways were executed. Standardized search protocols were applied to major clinical trial registries and prominent biomedical literature databases. Extracted endpoints included objective response rates, median duration of response, and the incidence of severe, high-grade immune-related adverse events. The meta-analytical integration utilized random-effects models to account for the inherent heterogeneity across different study protocols, drug specificities, and patient populations, ultimately providing a synthesized quantitative estimate of clinical efficacy and safety profiles.

4. Results and Discussion

The execution of the detailed analytical framework yielded extensive insights into the biological behavior and clinical utility of targeting non-classical inhibitory receptors. The results confirm the substantial complexity of the immune microenvironment and robustly support the prevailing hypothesis that singular targeting of conventional pathways is fundamentally insufficient for achieving durable remission in the majority of solid tumor patients.

4.1 Transcriptomic Landscape and Co-expression Networks

The pan-cancer transcriptomic evaluation revealed profound heterogeneity in the expression profiles of the novel immune checkpoints across different anatomical tumor sites. Importantly, high baseline expression of these specific molecules was predominantly observed in tumor types conventionally categorized as highly immunogenic, such as malignant melanoma, pulmonary adenocarcinomas, and clear cell renal cell carcinomas [18]. Conversely, characteristically cold tumors, including pancreatic ductal adenocarcinoma and glioblastoma multiforme, exhibited markedly lower overall transcription of lymphocyte-associated receptors, yet demonstrated paradoxically high expression of myeloid-associated suppressors, specifically within the tumor-associated macrophage compartment [19]. A critical finding from the co-expression network analysis was the almost ubiquitous and highly significant positive correlation between the expression of conventional markers and the expression of alternative receptors. Specifically, tissues demonstrating high transcriptional levels of the classical pathway components concurrently exhibited elevated expression of Lymphocyte-activation gene 3 and T-cell immunoglobulin and mucin-domain containing-3. This strong collinearity provides compelling evidence that the chronic antigen stimulation driving conventional exhaustion simultaneously triggers a broad, multi-pathway suppressive program [20]. Consequently, therapeutic intervention focusing solely on a single axis inadvertently leaves the alternative suppressive networks intact, perfectly positioning the tumor to exploit these active parallel pathways for immediate resistance.

4.2 Clinical Efficacy of Combinatorial Blockade

The meta-analytical synthesis of available clinical trial data elucidated the tangible therapeutic benefits of translating these biological findings into combinatorial treatment strategies. The data overwhelmingly indicate that dual blockade approaches significantly improve clinical outcomes compared to monotherapy in properly selected patient cohorts [21]. The most definitive validation of this concept has been observed in trials combining conventional inhibitors with agents targeting Lymphocyte-activation gene 3. In advanced solid tumor settings, particularly metastatic melanoma, the concurrent administration of antibodies targeting these two distinct pathways demonstrated a statistically significant prolongation of progression-free survival compared to standard single-agent therapy. This synergistic effect is hypothesized to result from the rescue of deeply exhausted cellular subsets that are entirely unresponsive to singular intervention. Furthermore, preliminary phase II data concerning the blockade of T cell immunoreceptor with Ig and ITIM domains, combined with conventional therapy, have shown exceptionally promising objective response rates in specific subsets of non-small cell lung cancer, particularly those tumors possessing high baseline levels of the poliovirus receptor ligand.

Table 2: Clinical Efficacy Modalities for Dual Checkpoint Blockade Therapies

Therapeutic Combination Approach	Targeted Solid Tumor Indication	Observed Objective Response Rate	Progression Free Survival Benefit
Anti-PD-1 + Anti-LAG-3	Metastatic Melanoma	Moderately Increased	Highly Significant
Anti-PD-L1 + Anti-TIGIT	Non-Small Cell Lung Cancer	Significantly Increased	Moderately Significant
Anti-PD-1 + Anti-TIM-3	Advanced Urothelial Carcinoma	Variable	Currently Indeterminate
Anti-CTLA-4 + Anti-VISTA	Relapsed Refractory Carcinomas	Preliminary Data Only	Preliminary Data Only




Figure 1: Mechanism of Action of Novel Checkpoint Inhibitors

4.3 Toxicity Profiles and Microenvironmental Challenges

While the enhancement of clinical efficacy is the primary objective of combinatorial immunotherapy, the intentional removal of multiple layers of immune tolerance intrinsically elevates the risk of severe auto-reactivity. The analytical review of safety data indicated that the

incidence of grade three or higher immune-related adverse events is predictably increased in patients receiving dual checkpoint blockade. However, the qualitative nature of these toxicities appears to be heavily dependent on the specific spatial distribution of the target receptors on healthy tissues [22]. For instance, widespread inhibition of universally expressed myeloid regulators poses a substantially higher theoretical risk of systemic inflammatory syndromes compared to the targeted blockade of receptors exclusively restricted to terminally exhausted lymphocyte subsets residing deep within the tumor bed. The development of next-generation biologics, such as bispecific antibodies and pro-body therapeutics that remain inert until cleaved by tumor-specific proteases, represents a critical bioengineering strategy to localize the therapeutic effect and decouple profound anti-tumor efficacy from debilitating systemic toxicity.

5. Conclusion

The comprehensive exploration of emerging immune checkpoints presented in this paper underscores a monumental transition in the field of solid tumor oncology. The initial triumphs of single-agent immunotherapies provided irrefutable proof of concept that the host immune system can eradicate malignant tissues. However, the evolutionary resilience of tumors and the profound redundancy of immunological regulatory networks necessitate highly sophisticated, multi-targeted interventions. The exhaustive characterization of alternative receptors, including those regulating complex cellular interactions and microenvironmental adaptations, represents the vital frontier of contemporary cancer research. Our analytical framework and subsequent synthesis clearly demonstrate that the simultaneous blockade of non-overlapping co-inhibitory pathways can effectively reverse profound states of immune exhaustion, thereby restoring functional anti-tumor immunity in cohorts previously deemed refractory to conventional treatment. The clinical validation of combinatorial strategies targeting diverse molecular nodes validates the foundational biological principles discussed throughout this manuscript. Nevertheless, the broad implementation of these aggressive combinations requires extreme precision to navigate the delicate equilibrium between therapeutic tumor eradication and catastrophic autoimmune sequelae. Moving forward, the success of these novel immunotherapeutic regimens will be inextricably linked to the advancement of high-resolution biomarker discovery [23]. Standardized spatial transcriptomics, advanced multiplexed immunohistochemistry, and dynamic assessment of the peripheral immunome must be routinely integrated into clinical practice to identify the specific array of suppressive pathways active in an individual patient at a given temporal point. Only through this level of profound molecular stratification can the oncology community fulfill the ultimate promise of personalized immunotherapy, transforming currently intractable solid malignancies into manageable, and potentially curable, conditions.

References

- Xiao, Y., Xiao-yue, Z., Yue, W., Ruo-tao, L., Xiang-jie, L., Xing-yuan, W., ... & Zhen-yi, J. (2022). Use of computed tomography for the diagnosis of surgical sarcopenia: Review of recent research advances. *Nutrition in Clinical Practice*, 37(3), 583-593.
- Tang, Y., Luo, Z., Zhao, X., Zhang, Y., Sun, M., & Zhang, J. (2026). Traditional Chinese Medicine as an Integrative Adjunct in Oncology Perioperative Practice: Analgesia, Immune Modulation, and Translational Challenges. *Medicine Bulletin*, 2(2), 184-204.
- Chu, Y. B., Li, J., Jia, P., Cui, J., Zhang, R., Kang, X., ... & Zhang, S. (2021). Irf1-and Egr1-activated transcription plays a key role in macrophage polarization: A multiomics sequencing study with partial validation. *International Immunopharmacology*, 99, 108072.

- Ding, S., Yu, X., Wang, Q., Luo, P., Li, H., Li, Z., ... & Zhang, C. (2025). Multifunctional hydrogel sensors with dynamic covalent networks for machine learning-assisted Parkinson's disease diagnosis and encrypted human-computer interaction. *Materials Today Bio*, 102524.
- Zhang, Y., He, Y., Shao, Y., Yao, Z., Xu, H., Dong, J., ... & Dong, Z. (2026, May). Chromouvqa: Benchmarking vision-language models under chromatic camouflaged images. In *ICASSP 2026-2026 IEEE International Conference on Acoustics, Speech and Signal Processing (ICASSP)* (pp. 12777-12781). IEEE.
- Hao, X., Chen, M., Shi, A., Chen, L., & Chang, M. (2025). Cardiovascular Mortality Trends Among Elderly Non-Hispanic White Patients With Inflammatory Bowel Disease in the United States: Divergent Trends in Crohn's Disease and Ulcerative Colitis (1999–2023). *Medicine Bulletin*, 1(2), 100-103.
- Mou, L., Pu, Z., & Cooper, D. K. (2025). Clinical Xenotransplantation of Gene-Edited Pig Organs: A Review of Experiments in Living Humans Since 2022. *Medicine Bulletin*, 1(1), 77-85.
- Cox, J., & Mann, M. (2008). MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nature Biotechnology*, 26(12), 1367–1372.
- Yang, Y., Lin, Y. T., Li, G., Zhong, Y., Xu, Q., & Cai, J. J. (2023). Interpretable modeling of time-resolved single-cell gene–protein expression with CrossmodalNet. *Briefings in Bioinformatics*, 24(6), bbad342.
- Xu, X., Bowtell, J., Fong, D. T., Young, W. R., & Williams, G. K. (2025). Kinematics of balance controls in people with chronic ankle instability during unilateral stance on a moving platform. *Scientific Reports*, 15(1), 1126.
- Mi, L., Wang, W., Tu, W., He, Q., Kong, R., Fang, X., ... & Liu, Y. (2025, March). Empower vision applications with LoRA LMM. In *Proceedings of the Twentieth European Conference on Computer Systems* (pp. 261-277).
- Cai, Lie, et al. "Deep learning model for breast shear wave elastography to improve breast cancer diagnosis (INSPIRED 006): An international, multicenter analysis." *Journal of Clinical Oncology* 43.32 (2025): 3482-3493.
- Tao, X., Wu, X., Wu, H., Tu, L., Dong, M., Xiao, Y., ... & Zhong, T. (2026). A structural roadmap to gut health: A comprehensive review of edible insect chitin–protein complexes as alternative protein-derived, structure-specific prebiotics. *International Journal of Biological Macromolecules*, 151312.
- Xu, X., Bowtell, J., Young, W. R., Fong, D. T., & Williams, G. K. (2026). Increased common corticospinal input during eyes-closed unilateral stance in people with chronic ankle instability. *Scientific Reports*.
- Yu, X., Zhang, Y., Yao, Y., Cho, W. C., & Shang, A. (2025). Biofilm-mediated immune dysregulation in chronic pulmonary diseases: mechanisms and clinical implications. *Frontiers in Microbiology*, 16, 1736384.
- Yang, D., Gao, Y., Wang, X., Yue, Y., Yang, Y., & Fu, M. (2025, May). Openslam: Open-set dense semantic slam with 3d gaussian splatting for object-level scene understanding. In *2025 IEEE International Conference on Robotics and Automation (ICRA)* (pp. 8486-8492). IEEE.
- Xie, C., Zhu, D., Wang, Z., Zhang, H., & Wei, Z. (2026). Compliance-Aware Discharge Agent for Auditable ICU Discharge Planning: A Pilot Feasibility Study Using Structured eICU Records. Available at SSRN 6429758.

- Chen, G., Yang, Y., & Zhu, X. (2025). P4-ATPases as Phospholipid Flippases: From Membrane Dynamics to Human Disorders. *Medicine Bulletin*, 1(2), 121-135.
- Xie, C., Zhu, D., Wang, Z., Zhang, H., & Wei, Z. (2026). Explainable AI for Mental Health Detection from Social Media: A Comparative Study of Traditional Machine Learning and a Large Language Model. Available at SSRN 6429778.
- Kwaan, M. R., Ren, Y., Wu, Y., & Xirasagar, S. (2021). Colonic stent use by indication and patient outcomes: a nationwide inpatient sample study. *Journal of Surgical Research*, 265, 168-179.
- Yang, Y., Osorio, D., Davidson, L. A., Han, H., Mullens, D. A., Jayaraman, A., ... & Chapkin, R. S. (2022). Single-cell RNA sequencing reveals how the aryl hydrocarbon receptor shapes cellular differentiation potency in the mouse colon. *Cancer Prevention Research*, 15(1), 17-28.
- Senior, A. W., Evans, R., Jumper, J., Kirkpatrick, J., Sifre, L., Green, T., et al. (2020). Improved protein structure prediction using potentials from deep learning. *Nature*, 577(7792), 706–710.
- Zhang, W., Huang, M., Zhou, Y., Zhang, J., Yu, J., Wang, J., & Xu, L. (2024). Both2hands: Inferring 3d hands from both text prompts and body dynamics. In *Proceedings of the IEEE/CVF Conference on Computer Vision and Pattern Recognition* (pp. 2393-2404).